110 related articles for article (PubMed ID: 20865695)
1. Preclinical comparison of intravenous melphalan pharmacokinetics administered in formulations containing either (SBE)7 m-β-cyclodextrin or a co-solvent system.
Koltun M; Morizzi J; Katneni K; Charman SA; Shackleford DM; McIntosh MP
Biopharm Drug Dispos; 2010 Nov; 31(8-9):450-4. PubMed ID: 20865695
[TBL] [Abstract][Full Text] [Related]
2. New injectable melphalan formulations utilizing (SBE)(7m)-beta-CD or HP-beta-CD.
Ma DQ; Rajewski RA; Stella VJ
Int J Pharm; 1999 Nov; 189(2):227-34. PubMed ID: 10536251
[TBL] [Abstract][Full Text] [Related]
3. Complex of 9-nitro-camptothecin in hydroxypropyl-beta-cyclodextrin: in vitro and in vivo evaluation.
Jiang Y; Sha X; Zhang W; Fang X
Int J Pharm; 2010 Sep; 397(1-2):116-21. PubMed ID: 20637848
[TBL] [Abstract][Full Text] [Related]
4. Cyclodextrins.
Stella VJ; He Q
Toxicol Pathol; 2008 Jan; 36(1):30-42. PubMed ID: 18337219
[TBL] [Abstract][Full Text] [Related]
5. Comparative effects of (SBE)7m-beta-CD and HP-beta-CD on the stability of two anti-neoplastic agents, melphalan and carmustine.
Ma DQ; Rajewski RA; Vander Velde D; Stella VJ
J Pharm Sci; 2000 Feb; 89(2):275-87. PubMed ID: 10688757
[TBL] [Abstract][Full Text] [Related]
6. Anticancer efficacy, tissue distribution and blood pharmacokinetics of surface modified nanocarrier containing melphalan.
Rajpoot P; Bali V; Pathak K
Int J Pharm; 2012 Apr; 426(1-2):219-230. PubMed ID: 22301424
[TBL] [Abstract][Full Text] [Related]
7. Influence of sulfobutyl ether beta-cyclodextrin (Captisol) on the dissolution properties of a poorly soluble drug from extrudates prepared by hot-melt extrusion.
Fukuda M; Miller DA; Peppas NA; McGinity JW
Int J Pharm; 2008 Feb; 350(1-2):188-96. PubMed ID: 17920217
[TBL] [Abstract][Full Text] [Related]
8. Probing a potential in vivo drug-excipient interaction: temporal effects of a modified β-cyclodextrin on the intravenous pharmacokinetics of a model high-affinity drug ligand.
Mannila A; Morizzi J; Nguyen TT; Charman SA; McIntosh MP; Shackleford DM
J Pharm Sci; 2012 Sep; 101(9):3381-9. PubMed ID: 22549698
[TBL] [Abstract][Full Text] [Related]
9. In vitro and in vivo evaluation of a sulfobutyl ether beta-cyclodextrin enabled etomidate formulation.
McIntosh MP; Schwarting N; Rajewski RA
J Pharm Sci; 2004 Oct; 93(10):2585-94. PubMed ID: 15349968
[TBL] [Abstract][Full Text] [Related]
10. Inclusion complexation of diazepam with different cyclodextrins in formulations for parenteral use.
Holvoet C; Heyden YV; Plaizier-Vercammen J
Pharmazie; 2005 Aug; 60(8):598-603. PubMed ID: 16124403
[TBL] [Abstract][Full Text] [Related]
11. Effect of 2-hydroxypropyl-beta-cyclodextrin on the solubility, stability, and pharmacological activity of the chemical delivery system of TRH analogs.
Wu WM; Wu J; Bodor N
Pharmazie; 2002 Feb; 57(2):130-4. PubMed ID: 11878189
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of new propofol aqueous solutions for intravenous anesthesia.
Trapani A; Laquintana V; Lopedota A; Franco M; Latrofa A; Talani G; Sanna E; Trapani G; Liso G
Int J Pharm; 2004 Jun; 278(1):91-8. PubMed ID: 15158952
[TBL] [Abstract][Full Text] [Related]
13. Inclusion complexes of tadalafil with natural and chemically modified beta-cyclodextrins. I: preparation and in-vitro evaluation.
Badr-Eldin SM; Elkheshen SA; Ghorab MM
Eur J Pharm Biopharm; 2008 Nov; 70(3):819-27. PubMed ID: 18655829
[TBL] [Abstract][Full Text] [Related]
14. Lack of effect of beta-cyclodextrin and its water-soluble derivatives on in vitro drug transport across rat intestinal epithelium.
Zheng Y; Zuo Z; Chow AH
Int J Pharm; 2006 Feb; 309(1-2):123-8. PubMed ID: 16359834
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics of high-dose intravenous melphalan in patients undergoing peripheral blood hematopoietic progenitor-cell transplantation.
Pinguet F; Martel P; Fabbro M; Petit I; Canal P; Culine S; Astre C; Bressolle F
Anticancer Res; 1997; 17(1B):605-11. PubMed ID: 9066587
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of cholesterol depletion as a marker of nephrotoxicity in vitro for novel β-cyclodextrin derivatives.
Wang H; Xie X; Zhang F; Zhou Q; Tao Q; Zou Y; Chen C; Zhou C; Yu S
Food Chem Toxicol; 2011 Jun; 49(6):1387-93. PubMed ID: 21426923
[TBL] [Abstract][Full Text] [Related]
17. Preparation, characterization and in vivo evaluation of formulation of baicalein with hydroxypropyl-beta-cyclodextrin.
Liu J; Qiu L; Gao J; Jin Y
Int J Pharm; 2006 Apr; 312(1-2):137-43. PubMed ID: 16459034
[TBL] [Abstract][Full Text] [Related]
18. Influence of preparation method on itraconazole oral solutions using cyclodextrins as complexing agents.
Holvoet C; Vander Heyden Y; Plaizier-Vercammen J
Pharmazie; 2007 Jul; 62(7):510-4. PubMed ID: 17718191
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of carboxymethyl-beta-cyclodextrin with acid function: improvement of chemical stability, oral bioavailability and bitter taste of famotidine.
Mady FM; Abou-Taleb AE; Khaled KA; Yamasaki K; Iohara D; Taguchi K; Anraku M; Hirayama F; Uekama K; Otagiri M
Int J Pharm; 2010 Sep; 397(1-2):1-8. PubMed ID: 20600734
[TBL] [Abstract][Full Text] [Related]
20. In vitro and in vivo evaluation of oral tablet formulations prepared with ketoconazole and hydroxypropyl-beta-cyclodextrin.
Taneri F; Ozcan I; Guneri T
Drug Deliv; 2010 Apr; 17(3):152-7. PubMed ID: 20148713
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
